nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults
|
Vasu, Sumithira |
|
|
6 |
4 |
p. 1342-1349 |
artikel |
2 |
Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome
|
Gerds, Aaron T. |
|
|
6 |
4 |
p. 1152-1161 |
artikel |
3 |
Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia
|
Morimoto, Yuki |
|
|
6 |
4 |
p. 1100-1114 |
artikel |
4 |
Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI
|
Khorana, Alok A. |
|
|
6 |
4 |
p. 1212-1221 |
artikel |
5 |
Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission
|
Sukumar, Senthil |
|
|
6 |
4 |
p. 1264-1270 |
artikel |
6 |
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia
|
Lyski, Zoe L. |
|
|
6 |
4 |
p. 1207-1211 |
artikel |
7 |
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
|
Rijneveld, Anita W. |
|
|
6 |
4 |
p. 1115-1125 |
artikel |
8 |
Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
|
Kwiatkowski, Janet L. |
|
|
6 |
4 |
p. 1243-1254 |
artikel |
9 |
Eculizumab for refractory thrombosis in antiphospholipid syndrome
|
Hussain, Habiba |
|
|
6 |
4 |
p. 1271-1277 |
artikel |
10 |
Editorial Board
|
|
|
|
6 |
4 |
p. i |
artikel |
11 |
Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study
|
Lissitchkov, Toshko |
|
|
6 |
4 |
p. 1089-1094 |
artikel |
12 |
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
|
Bataller, Alex |
|
|
6 |
4 |
p. 1193-1206 |
artikel |
13 |
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
|
Castellino, Alessia |
|
|
6 |
4 |
p. 1350-1360 |
artikel |
14 |
Gata2 +9.5 enhancer regulates adult hematopoietic stem cell self-renewal and T-cell development
|
You, Xiaona |
|
|
6 |
4 |
p. 1095-1099 |
artikel |
15 |
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
|
Delforge, Michel |
|
|
6 |
4 |
p. 1309-1318 |
artikel |
16 |
Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
|
Brem, Elizabeth A. |
|
|
6 |
4 |
p. 1361-1364 |
artikel |
17 |
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
|
Seymour, John F. |
|
|
6 |
4 |
p. 1365-1370 |
artikel |
18 |
Momelotinib is a highly potent inhibitor of FLT3-mutant AML
|
Azhar, Mohammad |
|
|
6 |
4 |
p. 1186-1192 |
artikel |
19 |
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
|
Gregory, Gareth P. |
|
|
6 |
4 |
p. 1232-1242 |
artikel |
20 |
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
|
Tam, Constantine S. |
|
|
6 |
4 |
p. 1296-1308 |
artikel |
21 |
Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
|
Kuczmarski, Thomas M. |
|
|
6 |
4 |
p. 1126-1136 |
artikel |
22 |
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
|
Voorhees, Timothy J. |
|
|
6 |
4 |
p. 1255-1263 |
artikel |
23 |
Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
|
Gagelmann, Nico |
|
|
6 |
4 |
p. 1222-1231 |
artikel |
24 |
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
|
Nastoupil, Loretta J. |
|
|
6 |
4 |
p. 1143-1151 |
artikel |
25 |
Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion–associated myeloid neoplasm
|
Miltiadous, Oriana |
|
|
6 |
4 |
p. 1137-1142 |
artikel |
26 |
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
|
Mascarenhas, John |
|
|
6 |
4 |
p. 1162-1174 |
artikel |
27 |
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
|
Martínez-Cuadrón, David |
|
|
6 |
4 |
p. 1278-1295 |
artikel |
28 |
T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity
|
Lum, Su Han |
|
|
6 |
4 |
p. 1319-1328 |
artikel |
29 |
Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia
|
Leahy, Allison Barz |
|
|
6 |
4 |
p. 1175-1185 |
artikel |
30 |
Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001
|
Tran, Thai Hoa |
|
|
6 |
4 |
p. 1329-1341 |
artikel |